Clinical Trial Results:
Randomized Phase II trial with safety run-in phase evaluating low-dose azacitidine, all-trans retinoic acid and pioglitazone versus standard dose azacitidine in patients >=60 years with acute myeloid leukemia (AML) who are refractory to standard induction chemotherapy (AMLSG 26-16 / AML-ViVA)
Summary
|
|
EudraCT number |
2016-000421-39 |
Trial protocol |
DE |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
21 Aug 2021
|
First version publication date |
21 Aug 2021
|
Other versions |
|
Summary report(s) |
Final Report_AMLSG 26-12/AML-ViVA |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.